Assessing FIGS (FIGS) Valuation After A Sharp Pullback And Strong Longer Term Gains

FIGS stock in focus after recent performance shift

FIGS (FIGS) is drawing attention after a recent pullback, with the stock down 9.3% over the past day and 10.5% over the past week, following a strong past 3 months.

See our latest analysis for FIGS.

The recent pullback sits against a much stronger backdrop, with a 30 day share price return showing a 4.7% decline, a 90 day share price return of 29.0% and a 1 year total shareholder return of about 3x. Recent moves suggest momentum has cooled in the short term, while longer term holders have still seen very strong gains.

If this kind of sharp swing in sentiment has you looking beyond a single stock, it could be a good time to scan for other opportunities in healthcare and related fields using our screener for 33 healthcare AI stocks

With FIGS stock pulling back after a strong 90 day run yet still sitting below the average analyst price target, the key question for you is whether this reset offers value or whether the market is already pricing in future growth.

Most Popular Narrative: 93.8% Overvaluled

According to the most followed narrative, FIGS's fair value is set at $7.21, well below the last close at $13.97. This frames the latest pullback as a move within an already stretched valuation story.

The company, on an absolute basis, is still growing well. Further, it has several growth levers, such as expanding its product range, entering new markets, and leaning into its “TEAMS” offering.

Read the complete narrative.

Want to see what kind of growth, margins and future valuation multiple need to line up for that fair value to make sense? The narrative leans on brand strength, expansion plans and a premium pricing model to justify the gap between fundamentals and price.

Result: Fair Value of $7.21 (OVERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, the thesis could quickly wobble if revenue growth continues to slow or if premium pricing meets resistance from cost conscious healthcare buyers, which could pressure margins and weaken brand momentum.

Find out about the key risks to this FIGS narrative.

Next Steps

With sentiment divided between risks and rewards, it makes sense to move quickly and weigh the full picture for yourself using 3 key rewards and 1 important warning sign

Looking for more investment ideas?

Do not stop your research with a single stock. Broaden your watchlist using focused screeners that surface opportunities you might otherwise miss.

• Target potential value by reviewing companies that appear mispriced on quality and fundamentals through 48 high quality undervalued stocks.
• Prioritize resilience by scanning for companies with healthy financial footing using the solid balance sheet and fundamentals stocks screener (44 results).
• Hunt for future standouts by filtering for high quality companies that are not widely followed through the screener containing 25 high quality undiscovered gems.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com